Bucindolol - Oruka Therapeutics
Alternative Names: BMY 13105; Bucindolol hydrochloride; Gencaro; MJ 13105; MJ 131051Latest Information Update: 03 Sep 2024
At a glance
- Originator Bristol-Myers Squibb
- Developer Medtronic; Oruka Therapeutics
- Class Anti-ischaemics; Antiarrhythmics; Benzonitrile; Heart failure therapies; Indoles; Phenyl ethers; Propanolamines; Small molecules; Vasodilators
- Mechanism of Action Beta 1 adrenergic receptor antagonists; Beta 2 adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Atrial fibrillation
- Discontinued Heart failure; Myocardial infarction
Most Recent Events
- 29 Aug 2024 ARCA biopharma Inc has merged with Oruka Therapeutics to form Oruka Therapeutics
- 04 Jan 2022 Efficacy and safety data from phase IIb/III trial in Atrial fibrillation released by ARCA biopharma
- 28 Jul 2021 Efficacy and pharmacodynamics data from a phase IIb/III trial in Atrial fibrillation released by ARCA BioPharm